



Practitioner's Docket No. **MP103-043P1RNM**

1PW
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Michael E. Hepperle et al.

Application No.: 10/821,545

Group No.: 1626

Filed: April 9, 2004

Examiner: Rebecca L. Anderson

For: BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed:

- (x) Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

- () After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but before the mailing date of either:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Sean Hunziker/Beverly Sotiropoulos
(type or print name of person certifying)

Date: May 25, 2006

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MP103-043P1RNM

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

OR

☐ The information disclosure statement transmitted herewith is being filed *after* a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

☐ In accordance with the requirements of 37 C.F.R. Section 1.97(d):

A. ☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

B. ☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

C. ☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

Practitioner's Docket No. MPI03-043P1RNM

FEE PAYMENT

3. ☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☒ Applicant believes no fee is due in connection with this submission.

		Fee due	\$0.00
METHOD OF PAYMENT OF FEE			
4. <input type="checkbox"/> Attached is a check in the amount of \$ _____.			
<input type="checkbox"/> Charge Account No. 501668 in the amount of		\$0.00	.

☐ A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

<u>May 25, 2006</u>	MILLENNIUM PHARMACEUTICALS, INC. By <u>Karoline K. M. Shair</u> Karoline K. M. Shair Registration No. 44,332 40 Landsdowne Street Cambridge, MA 02139 Telephone - 617-444-3227 Facsimile - 617-551-8820
---------------------	--



Practitioner's Docket No. **MPI03-043P1RNM**

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Michael E. Hepperle et al.

Application No.: 10/821,545

Group No.: 1626

Filed: April 9, 2004

Examiner: Rebecca L. Anderson

For: BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. [x] Preliminary Statements
2. [x] Form PTO/SB/08A (1 page) (substitute for Form PTO-1449)
3. [x] Identification of Listed Information Item(s) for Which No Copies Are Submitted or Need Be Submitted (A1-A3)
4. [x] Copies of Listed Information Items Accompanying This Statement (B6)
5. [x] Identification of Person(s) Making This Information Disclosure Statement

Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.



Signature
Sean Hunziker/Beverly Sothopoulos
(type or print name of person certifying)

Date: May 25, 2006

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI03-043PIRNM

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Identification of Listed Information Items for Which No Copies Are Submitted or
Need Be Submitted**

The cited references A1-A3 are not required to be provided in this application. However, the undersigned will provide copies upon request.

Copies of Listed Information Items Accompanying This Statement

A legible copy of all relevant portions of item reference B6 listed in Form PTO/SB/08A (substitute for Form PTO-1449) accompanies this information statement.


May 25, 2006

MILLENNIUM PHARMACEUTICALS, INC.

By Karoline K. M. Shairr

Karoline K. M. Shairr
Registration No. 44,332
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-444-3227
Facsimile - 617-551-8820

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

1995, no persons are required to

 DISCLOSURE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/821,545
Filing Date	April 9, 2004
First Named Inventor	Michael E. Hepperle
Group Art Unit	1626
Examiner Name	Rebecca L. Anderson
Attorney Docket Number	MPI03-043P1RNM

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

/Kristin Bianchi/

08/20/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.